Turn this list into pipeline.
Biotech Companies in Leeds: 34 Active Firms (2026)
Biotech companies in Leeds develop biological science-based therapies, diagnostics and research tools within the city's life-sciences economy.
Buying tends to sit with scientific founders, clinical-development teams, laboratory managers and commercial partners inside healthcare and life-sciences organisations. The Leeds cohort is more likely to sell specialist assays, preclinical packages, diagnostic validation, platform-biology access or outsourced laboratory capability than a standardised mass-market product. Engagements are usually technical and evidence-led: a customer may start with a feasibility study, service contract or research collaboration, then move into regulated quality, clinical or supply-chain workflows if the work holds up. That suits founder-led laboratories as well as small and mid-sized ventures with outsourced scientific operations.
Read more
Leeds has 34 actively trading biotech companies in this list, making it a compact local cohort rather than a broad regional cluster. Reported headcount totals 266 people, so the employment footprint is visible but still weighted towards specialist teams rather than large operating sites. The company mix looks consistent with early-commercial life sciences: laboratory services, diagnostics and research-tool businesses sit alongside therapeutics and platform-biology ventures, with many likely to depend on partnerships, grant-funded research, contract work or staged evidence generation before they reach fuller commercial scale.
UK biotech and biopharmaceutical activity sits inside the life-sciences regulatory framework rather than a light-touch market regime. The MHRA sets standards, evaluates new treatments, approves clinical-trial applications, assesses marketing authorisations and oversees safety monitoring after authorisation through pharmacovigilance. Trial-stage firms also have to work through Good Clinical Practice, ethics review and informed-consent requirements. For Leeds companies selling into therapeutic, diagnostic or biopharmaceutical supply-chain use cases, commercial traction is therefore tied to evidence quality, documentation discipline and the ability to satisfy healthcare procurement and assessment processes before routine public-healthcare adoption.
Leeds appears likely to remain a specialist, translational biotech market rather than a dense headquarters base for scaled therapeutic developers. The cohort’s shape points to patient, evidence-led commercialisation: lab-service and research-tool businesses can find earlier revenue, while therapeutics and diagnostics tend to face longer validation cycles, quality-system burden and market-access scrutiny. Scale-up scarcity may persist if later-stage capital and senior regulatory talent continue to concentrate elsewhere, although local healthcare, academic and contract-research demand should keep creating niches for firms that can bridge laboratory capability with regulated development needs.
34
Active firms
2026
2
Above £5M
reported revenue
9
Incorporated since 2022
newer registrations
Key facts
About 5% of the trading cohort reports turnover above £5M (2 of 34 firms) — the rest sits below that revenue band.
26% of the cohort was incorporated since 2022 (9 firms), so a sizeable share is in its first few filing cycles.
MHRA responsibilities include approving clinical trial applications, assessing marketing authorisations or drug licences, and post-authorisation safety monitoring through pharmacovigilance.
Clinical trials must follow Good Clinical Practice, ethics review and informed-consent requirements.
Approved medicines may be reviewed by NICE before routine NHS use, making health technology assessment part of the route to market.
The UK life-sciences industry generated £146.9 billion in turnover in 2023/2024, with biopharmaceutical companies accounting for £98.9 billion and 67% of the total.
BIA reported that the UK biotech sector raised £3.5 billion in equity investment in 2024, a 94% increase on the previous year and the highest annual figure since £4.5 billion in 2021.
Top Leeds biotech companies
LUNAC THERAPEUTICS LIMITED
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops anticoagulant drug candidates for the prevention and treatment of thrombotic blood clots. Conducts research and discovery of small‑molecule therapies targeting activated Factor XII (FXIIa)…
Serves the healthcare sector, targeting clinicians and organisations managing patients who need anticoagulant therapy for prevention or treatment of life-threatening thrombotic events.
Financial Health
DistressedDistressed · -29% CAGR over 2y
Location
Amo Pharma Limited
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops and advances pharmaceutical treatments for serious and rare diseases, including genetic, neuromuscular and central nervous system disorders. Conducts clinical research and drug development…
Serves patients and healthcare stakeholders focused on serious debilitating diseases, especially rare genetic disorders with neuromuscular or CNS symptoms such as congenital myotonic dystrophy,…
Financial Health
DistressedDistressed · -20% CAGR over 1y
Location
Develops and manufactures regenerative medical products using proprietary dCELL and BioRinse technologies. Processes human and porcine tissue to produce allograft and xenograft implants and grafts…
Serves hospitals, surgeons, other medical professionals and approved healthcare distribution partners in regenerative medicine, orthopaedics, musculoskeletal, dermis and soft-tissue care.
Location
Develops and manufactures regenerative medical products using decellularisation and tissue‑processing technologies. Processes human tissue allografts and porcine‑derived implants, and supplies…
Serves hospitals, surgeons and other medical professionals in regenerative medicine, plus approved distribution partners, across musculoskeletal, dermal, soft tissue and birth tissue clinical areas.
Location
Develops and manufactures regenerative medicine products, including processed human and porcine tissue grafts and implants for musculoskeletal and soft tissue repair. Uses proprietary…
Serves hospitals, surgeons and other medical professionals, plus approved healthcare distribution partners, in regenerative medicine markets for musculoskeletal, dermal, soft tissue and birth tissue…
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures research reagents including monoclonal and polyclonal antibodies targeting cardiac proteins and phosphorylation sites, along with kits and biochemical tools for studying…
Serves biomedical and cardiovascular research scientists, including academic and laboratory teams studying cardiac proteins, protein phosphorylation and S-palmitoylation.
Financial Health
StableStable · 0% CAGR over 4y
Location
ARTERIUS LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops polymer-based technologies for vascular medical devices, including drug‑delivery coating systems for angioplasty balloons and bioresorbable stent scaffolds designed to treat peripheral…
Serves global healthcare innovators developing vascular intervention products, including medical device companies, clinical partners and academic researchers focused on peripheral arterial disease…
Financial Health
DistressedDistressed · -91% CAGR over 2y
Location
ALTIMMUNE UK LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed · 0% CAGR over 2y
Location
Develops and manufactures regenerative medical products using decellularisation and tissue‑processing technologies. Produces allograft and xenograft implants, including ligament reconstruction…
Serves hospitals, surgeons and other medical professionals, plus approved distribution partners in the regenerative medicine and tissue-based products market across the US, UK and EU.
Location
Develops and manufactures regenerative medicine products including human tissue allografts and porcine tissue implants for musculoskeletal, dermal and soft‑tissue repair. Processes, stores and…
Serves hospitals, surgeons and other medical professionals, plus approved medical distribution partners in regenerative medicine markets, including musculoskeletal, dermis, soft tissue and birth…
Location
Develops and manufactures regenerative medicine products for surgical and wound care applications. Processes human and animal tissue to produce allograft and xenograft implants, including…
Sells B2B to hospitals, medical professionals and approved distribution partners in regenerative medicine, musculoskeletal, soft tissue and wound care. Serves healthcare providers in the USA and…
Location
Designs, develops, manufactures and markets sterile medical devices for sports medicine and orthopaedic surgery, including ligament and tendon reconstruction systems, surgical tapes, fixation devices…
Serves orthopaedic and sports medicine healthcare markets, especially surgeons, referring physicians and hospital or clinic facility staff; also engages medical product representatives, distributors…
Location
Platform Kinetics Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDesigns and manufactures custom scientific instruments, sensors and analytical systems. Provides product development from feasibility and prototyping to production, using electronics, imaging,…
Serves B2B customers, entrepreneurs and universities developing instrumentation, sensors and analytical systems for life sciences, pharma, agri-tech, food and feed diagnostics, and environmental…
Financial Health
StableStable · 0% CAGR over 2y
Location
Provides contract research organisation services to pharmaceutical, biotechnology and medical device companies, including clinical trial management, clinical pharmacology studies, data management,…
Serves biopharma, pharmaceutical, biotechnology and MedTech companies worldwide, including teams developing drugs, devices and diagnostics across Phase I–IV clinical programs and post-approval…
Location
Microneedle Solutions Ltd
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StrongStrong
Location
NANOPHARM LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides contract research and development services for nasal and inhaled drug products. Offers formulation development, particle engineering, spray characterization, analytical testing, in‑vitro and…
Serves pharmaceutical and biotech companies developing nasal and inhaled drug-device products, including innovators, generics manufacturers and teams managing lifecycle, reformulation or…
Financial Health
WeakWeak · Hiring · 13% CAGR over 2y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies ophthalmic diagnostic equipment including retinal imaging systems, fundus cameras, perimeters, microperimeters, and rebound tonometers, along with digital clinical tools used…
Serves ophthalmologists, optometrists, eye clinics and retinal screening providers involved in glaucoma, diabetic retinopathy and AMD care; also addresses patients using home tonometry.
Financial Health
StrongStrong · Growing, Hiring · 43% CAGR over 5y
Location
ASSEMBLIFY LIMITED
Trajectory
1y · 2024–NowFinancial Health
Insufficient historyInsufficient history
Location
ARITEX LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
Designs, develops and manufactures orthopaedic implant devices for joint replacement, including hip resurfacing systems and knee arthroplasty implants. Supplies products and clinical resources used…
Serves orthopaedic surgeons, hospitals and healthcare providers involved in hip and knee replacement, with resources also aimed at registrars, GPs and patients considering joint replacement.
Location
JENAVALVE PRODUCTION LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and manufactures transcatheter heart valve systems for treating structural heart disease, particularly severe aortic regurgitation. Produces the Trilogy transcatheter aortic valve…
Serves hospitals and specialist heart teams, including interventional cardiologists and cardiac surgeons, treating patients with severe aortic regurgitation or stenosis in registered markets.
Financial Health
HealthyHealthy · 3% CAGR over 2y
Location
PICTURA BIO LIMITED
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops diagnostic technology for rapid pathogen detection using image capture, fluorescence microscopy and computer vision. Platform analyses biological samples and identifies multiple infectious…
Serves healthcare and diagnostics organisations needing point-of-care infectious disease testing, including clinics, hospitals, laboratories and public health settings.
Financial Health
StableStable · -74% CAGR over 3y
Location
DON Whitley Scientific
Designs and manufactures laboratory equipment for microbiology and cell culture, including anaerobic, hypoxic and microaerobic workstations, incubators and isolators. Also supplies lab automation…
Serves B2B laboratory customers in microbiology, cell and tissue culture, pharmaceutical and tissue engineering sectors, including research, clinical and industrial labs.
Location
ETHOSS REGENERATION LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies synthetic bone graft materials used in dental implant surgery. Products are designed to support bone regeneration and eliminate the need for collagen membranes or donor grafts,…
Sells to dental implant clinicians, implantologists, specialist dental clinics and private practices worldwide, while also addressing patients considering implant treatment and clinics offering bone…
Financial Health
StableStable · -61% CAGR over 4y
Location
Genetica Group Ltd
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StableStable
Location
Technical IT Consultancy Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsManufactures microbiology consumables including transport swabs, dry swabs, hygiene sampling kits, pathogen identification kits, and microorganism preservation systems. Supplies products for…
Sells to B2B and institutional customers in clinical, laboratory and regulated sectors, including medical, veterinary, pharmaceutical, cosmetics, food and beverage, environmental, education and…
Financial Health
DistressedDistressed
Location
Sferola Ltd
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
WeakWeak · -50% CAGR over 1y
Location
S M C SOLUTIONS LTD
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsProvides contract manufacturing for medical device and pharmaceutical companies, including product design and development, tooling and mold design, silicone injection molding, sterile filling,…
Serves B2B customers in medtech, diagnostics and pharmaceutical sectors, including teams developing medical devices, autoinjectors and sterile drug-device products from prototype through commercial…
Financial Health
StableStable · Hiring · 12% CAGR over 1y
Location
CONCEPT MEDICINE LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures endovascular medical devices for cardiovascular treatment, including drug‑coated balloons, drug‑eluting stents and angioplasty catheters used in coronary and peripheral…
Sells primarily to healthcare professionals and healthcare providers involved in cardiovascular, coronary and peripheral interventions, and also addresses patients and caregivers seeking information…
Financial Health
WeakWeak · 0% CAGR over 4y
Location
REECE - JONES CONSULTING LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy · 0% CAGR over 4y
Location
Unlock all 34 leads
Showing 30 of 34 — +4 more with verified decision-maker contacts, live data, and CRM sync.
How Leeds biotech companies work and how to sell to them
What they do
Leeds biotech firms tend to earn through a mix of contract research, laboratory services, assay development, diagnostic validation, research-tool supply and intellectual-property licensing. Therapeutic and diagnostic ventures may have little conventional product revenue while evidence is being built, so income often comes from paid feasibility work, collaborations, grants, milestone payments or service contracts alongside longer-horizon licensing economics. Pricing is usually project-based, with scope tied to samples, protocols, analytical work, turnaround times and documentation requirements. For research tools and laboratory capability, buyers may pay per study, per batch, per test or through retained access to specialist technical capacity.
Who they sell to
Most buyers are technical or clinical rather than generalist budget holders. Typical customers include biopharmaceutical research teams, diagnostics developers, contract-research organisations, hospital-linked research groups, academic laboratories and public-healthcare stakeholders where validation or clinical adoption is involved. Decision-makers tend to include scientific founders, chief scientific officers, translational medicine leads, laboratory managers, quality heads, clinical-development teams and procurement once work moves beyond exploratory use. Simple research-service deals can be direct and relatively short-cycle; regulated diagnostics, preclinical packages and healthcare-facing collaborations usually involve scientific review, quality checks, legal negotiation and formal procurement, especially where NHS or pharma supply-chain access is part of the route to market.
What they buy
Most Leeds biotech firms tend to spend on laboratory inputs, scientific equipment, specialist consumables, outsourced assays, bioanalysis, preclinical support and quality documentation before they buy broad corporate systems. As they mature, common needs include laboratory information management, electronic lab notebooks, sample tracking, data storage, cyber security, finance operations, grant accounting, CRM, website content for technical audiences, recruitment support, IP advice, regulatory affairs, clinical operations, specialist insurance and health-and-safety services. Firms with outsourced scientific operations may be receptive to suppliers that help connect external labs, consultants and internal project teams without adding administrative friction or compromising traceability.
Why and how to sell to them
Biotech buyers tend to evaluate suppliers when a project moves from exploratory research into validation, preclinical planning, clinical evidence generation or partner due diligence. Other triggers include new funding, grant awards, senior scientific or quality hires, laboratory expansion, the first regulated customer, a planned MHRA-facing submission, or a shift from ad hoc service work to repeatable delivery. Pain points are usually practical: cash runway, audit readiness, sample traceability, reproducible experiments, data security, procurement burden and scarce specialist staff. Outbound works better when it links to one of those events and shows how the supplier reduces scientific, regulatory or operational risk, rather than promising generic growth.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Leeds
Related directories
Frequently asked questions
How many biotech companies are there in the Leeds?↓
What counts as a biotech company in this list?↓
Which are the largest biotech companies in the Leeds?↓
What do biotech companies in the Leeds actually do?↓
How does Leeds biotech compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical biotech companies in the Leeds?↓
Are these mostly new or established biotech companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 34 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.